CHMA - Earnings call transcript Q1 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Conference Call to discuss Chiasma's First Quarter 2020 Operating and Financial Results.

Our lines are in a listen-only mode and today's conference is being recorded.

At this time, I'd like to introduce Dawn Schottlandt, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Dawn Schottlandt

Thank you, operator.

our making not statements our plans limited potential of be circumstances, events development and will of clinical commercialization but timing data. manufacturing including to MYCAPSSA, release measures we of certain review supplements about forward-looking and and the our Today regulatory on and process, of expectations statements regarding

in Our to support MYCAPSSA sufficiency of plans and supplies expectations for commercial US the launch commercial States. launch, including the United our

Form our markets EU, cash any to approval our and statements of including future as as is XXXX, filed expectations. as Except as MYCAPSSA capital events law, XX-Q materially detailed may current efforts and March statements, new runway forward-looking approved. SEC the required with Actual SEC. on Our obtain or a with contained needs differ uncertainties, the and well ended those in quarter due to whether result regulatory composition for in of information, the obligation for These of anticipated the numerous of by size section to and results update risk disclaims factors information the based in XX, our these are our otherwise. potential MYCAPSSA filings subsequent the risks Chiasma

of Joining will President who President Clinical is Anand financial President, Development and and the Officer; Medical Fitzpatrick, Ludlam, Raj our Vice our Vice call and today Varadan, results. Chief Bill Executive Kannan, Executive Chief Senior Commercial Mark review Officer; Affairs;

the Executive Raj Officer to And now, Chief I Kannan. would call over Chiasma's turn to like Raj?

Raj Kannan

the highlights, to you XXXX joining financial results. discuss operating recent this first Thank call XXXX for afternoon Dawn. you, everyone quarter Thank anticipated milestone and our our

to on meeting, colleagues comment well by its our to virtual making we're new COVID-XX settings. Like, business. a of home environment. well Chiasma you, a have working and My me our the most and are and on adopting from adopted at start work Let few pandemic I impact

has standpoint crisis the from experienced COVID-XX minimal impact an to-date. So operational far Chiasma from

capsules FDA PDUFA we delay As not MYCAPSSA. Chiasma The you notified target fast date know XXXX PDUFA approaching June expected date. action our octreotide has XX, any investigational are to it's our for of

continuing are to an to chain commercial anticipated remains XXXX. fourth continue and quarter for for repeat supply date [ph] launch work contact our with will approval assuming The continue Chiasma We plan and in to manufacturing US we evaluate the the towards MYCAPSSA in close of suppliers. our team

commercial believe of support approval will approval to Assuming NDA supplement, we of have MYCAPSSA prior our manufacturing launch. the planned planned and we commercial supply our sufficient

the Lastly, in with a arm trial on COVID-XX total of controlled continuing XX the impact, randomized. empowered that it's six the patients active of were out patients randomized

to details, are sites met more the the trial. EMA of working sale with controlled requirement the the the of safety smooth randomized of trial note, ensure trial given the We the the and trial. minimum of patients to but of working randomized nine-month clinical of patients XX provide will Bill the the site a has

timely FDA quarter the is prior the the of planned As NDA approval XXXX we of a of planned supplement launch dependent of API approval previously, MYCAPSSA fourth commercial upon [indiscernible]. an our manufacturer, noted and approval

half PDUFA API manufacturer approval our expect this primary the of of we for supplier prior submit approval We date anticipate supplement following shortly continue XXXX. to to to API our continue our in planned second and

file manufacturing FDA plan data. include to we that approval, supplement prior that to in courts requested we certain approval planned Pertaining second our stability the April

request planned will delay this the API supplement We our responding submission expect manufacturer of second until early to that XXXX.

fourth MYCAPSSA. execute quarter We on commercial launch the we have of continue supply commercial to believe will to planned available

we're one prior planned of However, approval approval FDA now supplement. to on meet goal, dependent the the

commercial launch supplier this adequately expect the planned could MYCAPSSA. support We of

entered we development into engaged We launch Moving Healthcare on April, will to Chiasma as to success. several believe MYCAPSSA's MYCAPSSA. and known whose a to tier HCR beneficial the Partners interest partners, of million directly up commercial add with a highlights. who financing investment tied our to to a extensive $XX is support firm. due top it agreement options Royalty be investor After are ongoing to with revenue an process we returns evaluating our of diligence financing potential commercial conduct for and recent In and is partnered to careful

our Anand back the more Anand advising pleased was Vice has not anyone brought qualified Anand and as consultant of I'm in been President of and a time to Also Commercial on strategic Varadan launch in Officer. full since XXXX, Chief Chiasma Chiasma commercial Chief as Executive Commercial XXXX, back April, we he Chiasma extremely board and XXXX. planned the think execute of a Officer at could to have MYCAPSSA. early I

physician environment I'm we of for team virtual that we With may approved visit. in interface Anand, commercial at market. have reasonably given COVID-XX built to administration telehealth positioned including will confident world MYCAPSSA injectable means preferred with home if dominated model do the to shift its become Overall the a oral anticipated well hiring a believe customer be the navigate and the the right otherwise leadership

our Anand Anand? adapt With interface efforts the to initial call of MYCAPSSA highlight turn to environment. efforts that, some to I to will planned the customer commercialization new over our

Anand Varadan

Chiasma and some Thank first help if patients colleagues, the Like so MYCAPSSA be definitely Chiasma back looking bringing you, analog believed therapies. by really we potential of to my forward other somatostatin FDA. to the injectable innovation patients the in options let to excited alternative of the incredibly to by at I the really business, oral TPE We represented Raj. to returning company's providing I'm approved platform. I'm the felt the with that unfinished had achieve mission

level period customers our Let including face the face mandates. by our of for overview restricted social me distancing start may high to commercial access pre-launch with a planning providing when activities, the be

during MYCAPSSA believe better other disease be positioned will this in drugs than we world said, Raj time. COVID-XX As launching rare

the will a in oral injectables, First, by market only for be label administration. therapy HCP self-administered it dominated

current second, us our QX new as The to launch for our our from experiences to into learnings product based revise time for early environment the settle more in commercial and a planned needed promotional plans of in normal QX. on allows

who to and so acromegaly comfortable interaction. octreotide, Third, that research use mechanism increasing a other action. patients are will of significant an new market entirely with of shows lastly, treat of familiar endocrinologists not endocrinologists And means already their preliminary Telehealth are number and need become of with acromegaly they patients remote

strengthen treatment plans develop web-based implementing promotion. Our team nurses media educate has to programs spent by to significantly the our to campaign, remote and through borne personal patients, begun and weeks patients. non-branded revamping currently campaign adapted our on well promotional as burdens our We've acromegaly digital last and the tools several digital physicians as

Finally, approval. we've accounts customer tier top shortly team our begun and recruiting to facing after of coverage plan promotional have

marketplace full carefully in to the product the our promotional will when market evolution becomes monitor of the our We early team available. inform address up to and in efforts effectiveness commercial the scale of the

an to At I'd present this OPTIMAL point, CHIASMA trial. over Bill? our the to Ludlam and call MPOWERED the data like to on the update provide discuss to to plans turn Bill

Bill Ludlam

medical providers and ACE for ENDO, engaging education Anand. productive canceled in Thanks, and quarter healthcare the conferences, compensating a [ph]. medical remotely been ECE We the challenge affairs. with It has had for of including

and phone. and active MSLs connecting with very the to have in the through over using a pleased progress to with endocrinologist them reaching Our team's digitally quickly video remote working I'm ability environment. adapt been the

June in ENDO Conference which March has In the virtual data, canceled its XX. a terms OPTIMAL Annual X take the of through CHIASMA Society, presentation conference to of June the scheduled place

addition, we we to will in we available In several data all be our our publish ENDO of abstracts seven After next that weeks. website. Journal Endocrine able Society to anticipate via corporate in of our expect accepted the time, the make the

and Additionally, conference we at additional fall. the Virtual publish virtual this to conference June date OPTIMAL at ECE ACE CHIASMA expect in

we We also track to in are publish journal peer-reviewed believe in the OPTIMAL CHIASMA data a mid-XXXX. on

is phase trial active in RCT six the implement capsules randomized patients of been the at octreotide phase healthcare As nine-month the randomized trial. in MPOWERED RCT have working patients trial protocols sites Of XX I for and responders into remaining RCT. XX earlier and remained My Raj the team completed ongoing. the or safety to with mentioned controlled professionals the clinical the as have

We of XXXX Therefore has phase of met RCT requirement the of missing to trial. the report from are average primary values Importantly, primary or the the the of EMA results on the minimum anticipated analysis. remain trial this endpoint to a track will top nine-month to completion randomized be of TWA endpoint comparator patients in quarter IGF-X time The weighted study. XX fourth analysis. monthly line with calculated the effect not

management somatostatin the The in Lastly, to our patients medical we actively not disease or currently registry The office. US of macro registry conducted visits the acromegaly it physician's state analogues. was called are registry. the be to is such treatment multi-year acromegaly enroll to require remotely as meaning does injectable designed enrolling receiving registry registry continuing

on not COVID-XX As objectives. such, from we significant our enrollment a impact do expect

patients plans XX the to burdens sites, Our for of on treatments. and registry US yield of various and patients care, clinical state for over medical data associated important is the treatment current involve the hundreds effectiveness with real-world

Mark? to review will over that, financials. I to With turn Fitzpatrick the call the Mark

Mark Fitzpatrick

of US. XXXX. XXXX as compensation-related $X.X quarter ended General the million $X.X in increase with the potential administrative expenses period expenses in administrative other first increased results an the of Thank for you, for continuing commercialization our current and the we The prepare include pre-commercial period were Bill. same and for capsules XX, million March compared activities, octreotide costs

planned $X.X the state ended driven for trial our the literature $X.X if registry, same which support of scientific compared clinical and XXXX. to for manufacturing disease in approved, a costs, million Research and by decrease capsules launch, were our XX, increase regulatory the associated quarter increased were primarily octreotide with offset by was The expenses with million XXXX publications development commercial of costs. costs period first March

million a March ended a basic quarter with Partners In of cash or as $XX with compared $XX.X period XX, XX, or entered XXXX. and million, for the $X.XX April, the and marketable to $XX.X loss per $XX.X net as commercial March million share were basic MYCAPSSA. million XX, $X.XX loss launch net Cash, of interest or XXXX. into $X.X development equivalents same of for compared of financing revenue Chiasma the with million For HCR December up support XXXX, Royalty planned per Healthcare to agreement of XXXX share securities ongoing was

payment the company provided million XXXX, to approved June less received announced is us revenue previously MYCAPSSA expect be an financing million revenue by April HCR in If certain interest agreement. by $XX In FDA expenses July. $XX HCR in from we transaction a additional to the interest financing under in

call I will the Raj. back turn to now over

Raj Kannan

Mark. Thanks,

make potentially to we this the acutely few like to Before would with acromegaly. achieving year our in to comments. and We on a for analog stated remain option adult the plan opening somatostatin make approved, acromegaly. to MYCAPSSA oral If milestones standard the call pharmacological new of care with questions, I focused patients bringing patients first

the anticipated in the transformational As Chiasma. Bill to milestones, I the for world look despite challenges today, year XXXX current a at our be has potential

Our we we believe is PDUFA prepared target date of a XX, the execute action just June XXXX and commercial positive regulatory to MYCAPSSA are launch around outcome. assuming well successful for corner

the our therapies and develop we be more utilizing start to or one That of efforts materialize oral expansion RTB end Looking XXXX, pipeline discuss able platform. to towards our our to should concludes remarks. plan will

call for the your questions. open now Operator? will We

Operator

And Instructions] Capital from question Rahimi our Partners. with Thank [Operator will you. ROTH first Yasmeen come

Yasmeen Rahimi

Thanks, update you great especially on for you in into environment. progress, as the late we for continue questions Two detailed team. team. Thank this

mean regards can into to a give registry, What study? is, registry us utility How patients one color especially been COVID. the you many in you? is these little part of results bit enrolled first have the around The macro already with this more for

our is, question that stability related great bit doing? would questions. color us can regards were thank to study for little sorry, that you be to a second give studies just in the you delay launch the you then suitability and taking That you announced -- And more the

Raj Kannan

Thanks, Yasmeen.

the and question, I'll then Bill. it hand second me over sort take first Let comment make to a of and

support We launch we mentioned haven't The approval guidance be the launch. get the PDUFA delayed approval had we're we fourth be that would given prior that quarter. supplements the had we in is we before launch the that in our commercial of change expecting finding would after with to originally two shortly consistent that terms our

changed. timing the Now, has sequel and the

need after capable to we have our forecast. approval support this filing API our one we supplier would commercial So, primary that be supplier our right supplying PDUFA of is and fully

you a if gaps which details, it state-of-care today industries more over wanted into go documenting is really in focuses before and I but can want, first we on -- that So on [indiscernible], Bill, registry turn to the treatment. this identifying

generate do So as particular to the color to more could enable you registry trials? patient in to that and to to itself want help data improve HCP's data add the outcomes. Bill, registry

Bill Ludlam

a way Raj. great cheer to It was Thanks, Yes. up.

point all that So enrolling. registry this is set to is the

Our is is of XX up that ahead bring more moving Everything sites patients as target to and anticipation. XX our hundreds -- planned. or is

their COVID-XX You did specifically the remotely situations, sites remotely, can the do can design parts of very so done really it we fortunate things come ask and on in the it patients activate this remotely. way one were be the and in that of can trial is we and can

as ago, the the progressing as moment everything COVID-XX. very not stated, So a we fortunately, on by adversely impacted is just And planned. registry I've have been

Yasmeen Rahimi

market four And you share fundamentally the three, planning? question. the few now you market, Has a back? tell us as could than acromegaly looking years in that if than the is you, different the were resumed Bill. ask us may Can maybe all a Thank maybe ago quick you things I at extent when with anything you then Anand, commercial that years to changed

Raj Kannan

Anand?

Anand Varadan

Yasmeen. Thanks, Yes.

ever, sign also oral appreciation treatment and has strong that is thing fact for that So the it's unmet be -- changed burdens that's therapies speak found viewing of I clinicians since -- therapies is that few patients as now XXXX patients a very And needs these to though to strong of in market. I years what tell this to we've the yes, the thanks. when that -- on think that to heartened Thanks injectable the what with I'll now Raj. the the ago by to and there continue I'm there you we an are increased. say is a demand for option comparison that's

being that's that's the and that the hopeful understood, been of -- continue think that to of frame understand has work injectable for is the has preparation we intervening therapies on some better started which be launch a concerned, I is better to of much market patients as due as with And done helped get the to into a, sign far these to time consequences which to is it. good when in as

Yasmeen Rahimi

June. luck and into best team as the head you, Thank of we

Raj Kannan

Thank you, Yasmeen. Thank you.

Operator

Tsao with Wainwright. Next question will come from Douglas H.C.

Douglas Tsao

afternoon. Hi, Thanks for taking questions. good the

might injectable they maybe talk in allow clinicians the some to would remain that measures sort that a about talk Just some Can when about advantages work advanced sort need providing things you risk and maybe place that that think still significant are and second to and be on the of Obviously, biochemical possibility self-administer for launching there will to we to Bill disease MYCAPSSA we wave, there social in about of therapy of therapy speak. transition so distancing as the that MYCAPSSA. control? patient at thing comfort of move the

Raj Kannan

Yes. Douglas. Thanks,

seamless in to terms think at patients quarter hand physician's we of and making the last switching in than sales the to for have We and placed importantly from them we and supervisor, office as tools away in would been absolute launch a better would system One, trade office provide before over and burden or top-tier couple overarching an world-class patients. relatively always our that really the sure think be. ability has have switching the of strategy high pivot on the physician's where I the nurses it Anand. I said more focus And that the before, in fourth positions that allow to do support week. week a speaking launch this think I launch I customers have comments companies

terms we speak In adoption in MYCAPSSA. utilization drive particular, current have of I'll our the let and we recent and how Anand did confident what we feel to the are, able findings to Anand? and in plans the that that the survey that endocrinologists be moved have environment we and should why of

Anand Varadan

Yes. Raj. Thanks,

who is things necessarily to moving itself is, especially communications. lends towards because and their other kinds Doug, has to mentioned of other COVID-XX those referring these acromegaly sort been of how a that to patients to can environment. that don't the these this they they're strongest So clinicians they the I have did telemedicine to of remote -- forms of kinds practices of -- that, endocrinologists, as think specialties. large from came part involved interaction out that that those research we of of Raj in my one among survey the of treat strongly interventions of in due in that evolve most prepared is the to And I understand it more in be that's, have And fact remarks with

question, to console your oral yes, MYCAPSSA needs in can the therapy. patient. be we the and is all answer be with -- suited point the environment orally well also -- done that of because contact And free octreotide an be this can from MYCAPSSA form to for well. telemedicine done to everything the But as what stabilization it's

fashion And patient ongoing therapy then process. data need that stabilizes strength so order the of evident the as until I that led in to think of on all that battle those is be conversion to to is happen including what done might well can the the in measurements part a and this remote the

Douglas Tsao

clarify to to confirm or just point. just So, that

up hear period of the come They and company. this welcome of done can office, sort this finalizing patient, may sort again also go of sort basis to of telemedicine a remote on a the to we to dose. and -- your Anand don't through you sort of just you be back as -- measured and So titrating get into the as sort need

Anand Varadan

be you. needed a the to make talk need have need any communicated can adjustments for to those but well. great they to are to results remotely do doesn't blood as to clinicians drawn, -- back can their Doug. practice lab yes, dosing Thanks, no, And, that the to patient It's it they and absolutely need does then be remotely sent

contact can So in in happen the really can lab it in that. and or home are up the in able only sent provide patients' draw country needs be order where that the blood that be they to to just done the part the location is around to go and to that sites of to

those manner. done So dimensions be in different can that all of

Douglas Tsao

final you'll one you the [indiscernible]? their just home may sort in to And blood question way necessarily patients quick or going getting of presumably of their than -- sort like drawn treatments facilitating a at a easier

Anand Varadan

Yes.

have providing facility that will of We done the basis. can to into even where a lab patients at disposal they not a be out, can they patients' too. on to the clinician they of be Many just done where them option go that done advantage want though venture which options in home, remote we sent But have their today them, an there. of additional the the don't take of if have plan their can be and is It whatever so choices. to provide to into directing blood are to

Douglas Tsao

much on great. and you Thank all the Okay, progress. so congrats

Raj Kannan

Doug. you, Thank

Operator

with from next Folkes Cantor question Our will Fitzgerald. come Brandon

Brandon Folkes

and one with can it any that fair equal just questions ask supply? on Can there? you you if what and it's for that which finally your the I or Hi. supplies potentially commercial estimate think XX%, the think supplier and just taking I an would is the percentage what color market Thanks for supplied you question, at can elaborate just we help the provide Maybe about of is progress. following us supply. on capacity from congratulations earlier my thinking mean, you

bit then confirm had you and got stability data And in one the hopped little one suppliers data, FDA of other correct? the but I And just is the from so stability more. from requested to late, supply that that I've

Raj Kannan

one or be finish you first? Okay. answer this to questions going Brandon, are to the

Brandon Folkes

it's answer is want you -- bit to other a got the do subject. different a one Raj, this because of one

Raj Kannan

plan comments, prepared fully shortly capable answer we have second data after The taxability Yes. diversify, prior mentioned particular PDUFA primary commercial data. did question, our had It's to file needs. as our for or not but need to we supplier a and to we put first approval. supplement secondary stability of in the manufacturer that to We produce because your sort approval plan we of to that supporting

that are in your supplement answer filing side Does early looking now at approval question, XXXX. that Brandon. We

Brandon Folkes

if It does. you I headroom hit a bit and run supplier? more how the detail much cost, there do little just maybe wanted have one of, you -- with full us to in terms do

Raj Kannan

to and in to added we've one to but base commercial forecast in mitigating at give you of diversify chain. Brandon's manufacturer. So answer, have supplier Mark little to our had I'll it or question. that own over API more any add second across continue always comments with I'll that of we look he our a API more We just give the value hand March, manufacturer, capability may detail, supplying of risk to our diversifying terms to manufacturing our it any other the

Mark Fitzpatrick

Raj. Thanks, Yes.

two that So three we is in that didn't of has two sites. of and the our been the they of Bachem one scaled has want between as want companies NDA. doesn't of sites, order is have supplement six location yet. stability Brandon. because approval down months to we relationships to particular always review clinical didn't manufacturers. And One stability new a both data trial that it's new the those We of resubmission, up They process location, the the prior and to It other for the the slow complete manufacturers the years. include resubmitted manufacturing company for have these them material years all -- in new had from the the over Teva APR have

So year supplement year. lead to going expect available early in, next will will be that later data this the that we stability and

CMOs operational suppliers. API and a of without The are as well. our the we've ordered to suppliers from from in But suppliers standpoint, produce the both and finished running up interruptions capacity from product

driven of prior challenges the any [indiscernible]. So now-sequencing we supply particular approval supplements having manufacturing with anticipate the don't

Brandon Folkes

Thank the next the sort a talked you on both very That's Great. from about We just helpful. to in. following again. And in bit those switching switching then, so controlled well what patients can being you lot just would to a goes who MYCAPSSA question long-acting of terms in injectable. COVID actually injectables little to MYCAPSSA, long-acting my elaborate a be back into of but bit of patients a not

that successful initially a confidence should terms what may so in is be MYCAPSSA the it patients? Just physician have controlling not in using involved, of that,

Raj Kannan

So, great question, Brandon.

In terms of the within then to to their trial we revert itself, control as you the would that were have came back noted, through arms two that saw the four injection right, had they we when this with we and that one had anything, back week in, is about according they expectation. not which to it's had reason MYCAPSSA features the MYCAPSSA is import for with to easy or any injectable switch of tolerated injectable it with an doesn't the work and attractive physicians the they

goes switched more for own and itself trial provide with over to it profit into his from Bill little a about hand the back what I'll details to injectables.

Bill Ludlam

Yes, Brandon.

So the very short acting MYCAPSSA drugs. is

So you long-term around. need to worry don't hanging drug effects the of about

once all point. opt some opts, have again they overlap can to just simply just choose they they patient wanted taking go that if if at So they injectable injectable basically, and stop back they the would start the to can or to

injectable this injectable smooth that Now transition from back some even discuss should have and the some going fairly be so still for whatever through -- simply patient, reason, they simply a there the to we follow the going clinician a will effect, the the physician will back for patient oral if that if to MYCAPSSA of process. the to wanted reason expect go the we're patient even patient to felt

Raj Kannan

I we looked MYCAPSSA controlled arm, when chose add and that well saw patients you even they Yes. clearly And if were we're went stable on of trial our from on and and Brandon though to stable the on these oral XX% remain injectable. them to rate, at used an the were who even injectables

will in as that be point replicated is data think the So an world encouraging real that we well.

Brandon Folkes

very luck the Thank and [ph]. PDUFA you much Great. good for

Raj Kannan

Thanks, Brandon.

Operator

Tenthoff will And next we Ted from hear Piper. with

Ted Tenthoff

respect track thoughts very to earlier, you for normally since early questions of in on I terms the wanted a lot the maybe I of have lot been remain addressed. [ph] was the incurred With appears to PDUFA those make telemedical ask, really a Hi, a sense. secure to platform and much update. bit proprietary are thank even the and little be stretched for guidance by bit obviously, things are that? re-energize And company's Europe. a your you. technology, and level thoughts on out kind the nearly and in MYCAPSSA start But launch that pipeline? additional plans Thank your is would the focus at data on out of partnering what to to efforts little what of higher a efforts; are of

Raj Kannan

Great Ted. Thanks, question.

the approval is execute we our reiterate has sure we As to think in that and you closer to just which creation, investors imagine, the successful And adjacent we as and to absolutely so injectable are get launch already disease been get that can always focus and end where the NET launch. are do competitive on an have at state I looking value the starting to be make bigger is terms a closer mirror, investors of we as analog what the plan somatostatin to in where something approval once year always the participate and would speak. rearview which to is We're [ph]. of sandbox

area optimal to are. an ability to that what's looking I we what in end various targeted our and actually the the potentially commercially. molecule where the additional the looking medical get think also we're allocation, significant is a prospects where both unmet therapeutic So capital investment growth articulate we of year, of by long-term and of do certainly on It's we'll there sense need then best return at feel have sort we that of are a quite We attractive. our that the mid at terms

we of our you're be clear few want pipeline COVID-XX the sort to feasible a provide is any XXXX. terms obviously, doing and view in that to time, going given of even as plans don't to guidance this At where not provide for a things around

Ted Tenthoff

so Thanks sense. much and lot going all luck things healthy. on. a the makes and with all that Perfect, stay Thanks good

Raj Kannan

Ted. you, Thank Yes.

Operator

And queue, remarks. in over for Kannan no back to turn further like the closing the with Raj I'd call questions to

Raj Kannan

Thank you, operator.

acknowledge in patients potentially our concludes On of to entire the that would benefit therapy. would heroes. workers to today's and behalf very I the our all like good remain closing, you the to of are gratitude -- truly committed So all Thank to health-care who want all was MYCAPSSA to personnel, I call. And and bring to our organization, could fight from fighting employees engaged you. it services; who express the the frontlines, essential like on the

thank Have us. speaking all look you to evening. a And with throughout for quarter. joining good the again you forward We

Operator

again, conclude for our Thank Once you for today. and that ladies participation. gentlemen, call does your

disconnect. now may You

Chiasma (CHMA) 11 May 202020 Q1 Earnings call transcript